Last reviewed · How we verify
Brixadi
This drug has been discontinued, meaning it is no longer being developed. Further clinical information is unavailable due to the discontinued status.
At a glance
| Generic name | Brixadi |
|---|---|
| Also known as | Buprenorphine Injectable Product |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Boxed warnings
- WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo‐embolic events, including life-threatening pulmonary emboli, if administered intravenously. (5.1) Because of the risk of serious harm or death that could result from intravenous self‐admi
Common side effects
Key clinical trials
- Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (Phase 4)
- Assessing the Safety of Buprenorphine in People With Sickle Cell Disease (Phase 2)
- Functional Brain Mechanisms Underlying the Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder (Phase 4)
- Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (Phase 4)
- RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at th (Phase 4)
- A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable De (Phase 3)
- Healthy Minds Program for Veterans With Opioid Use Disorder on Buprenorphine Maintenance Treatment: A Pilot Study (NA)
- Buprenorphine Maintenance for Opioid Addicts (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brixadi CI brief — competitive landscape report
- Brixadi updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI